Clinical trials: Acute Ischemia
Myocardial Infarction
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
The purpose of the study is to determine whether adult stem cells [Provacel™(PUMP1)] are safe and possibly effective in the treatment of acute myocardial infarction (heart attack).
- Trial name
- NCT00114452
- Testing
- Provacel
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mesoblast, Inc.
Acute Ischemic Stroke From Large Vessel Occlusion
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (2.5mm or greater in diameter) occlusion…
- Trial name
- NCT01584609
- Testing
- Penumbra System with Separator 3D, Penumbra System alone
- Where
- 8 sites in United States
- Volunteers
- 198 people
- Sponsor
- Penumbra Inc.
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)
The objective of this study is to evaluate the efficacy and safety of the GENOSS SES in patients with acute coronary syndrome (ACS) in real-world pratice.
- Trial name
- GENOSS ACS (NCT06075368)
- Testing
- GENOSS Sirolimus Eluting Coronary Stent System
- Where
- South Korea
- Volunteers
- 757 people
- Sponsor
- Genoss Co., Ltd.
Acute Coronary Syndrome, Factor X
Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
This study is a clinical trial monocentric, open, randomized ENOXA ® versus LOVENOX ®, conducted on two parallel groups of patients admitted in emergency for acute coronary syndrome.
- Trial name
- AXA (NCT01687491)
- Testing
- ENOXA®, LOVENOX®
- Where
- Tunisia
- Volunteers
- 179 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Acute Ischemic Stroke
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
- Trial name
- NCT03062397
- Testing
- JPI-289 Low-dose, JPI-289 High-dose
- Where
- 15 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Acute Coronary Syndrome
"Me and My Heart" Study
An electronic device application (APP) "Mein Herz und ich" has been developed specifically for acute coronary syndrome (ACS) patients who are prescribed to Brilique (ticagrelor) to increase adherence to treatment (medication and…
- Trial name
- eMocial (NCT02615704)
- Testing
- Active group with MEMS, Active group without MEMS, Control group with MEMS
- Where
- 31 sites in Germany
- Volunteers
- 677 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin
This will be a double-blind, 4-period, randomized, cross-over study conducted in healthy adult subjects. The purpose of this study is to characterize the effect of orally administered losmapimod on the electrocardiogram (ECG)…
- Trial name
- NCT01756495
- Testing
- Losmapimod, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Cost Sharing, Acute Coronary Syndrome
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Current patterns of P2Y12 receptor inhibitor use provide an excellent opportunity to test the impact of copayment reduction on clinician choice of medication, patient adherence, and clinical outcomes.
- Trial name
- ARTEMIS (NCT02406677)
- Testing
- Study voucher card
- Where
- 272 sites in United States, Puerto Rico
- Volunteers
- 11,001 people
- Sponsor
- AstraZeneca
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)
The study is designed to assess safety and effects of vorapaxar, when added to standard of care (aspirin and clopidigrel), in Japanese subjects with acute coronary syndrome.
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00684203
- Testing
- Vorapaxar, Aspirin, Clopidogrel
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome
PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers
This clinical study will adopt an open-label, randomized, multiple-dose, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with…
- Trial name
- NCT05162053
- Testing
- vicagrel Capsules, Clopidogrel Tablets
- Where
- 3 sites in United States, China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
Optic Neuropathy, Ischemic
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
- Trial name
- NCT00759174
- Testing
- No intervention
- Where
- 105 sites in United States, France and 4 more
- Volunteers
- 673 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cerebral Stroke, Ischemic Attack, Transient
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.
- Trial name
- NCT00119626
- Testing
- NXY-059
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Coronary Arteriosclerosis, Acute Coronary Syndromes
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
The sponsors of this investigational drug are developing prasugrel (also known as CS-747) as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a…
- Trial name
- NCT00097591
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 13,619 people
- Sponsor
- Eli Lilly and Company
Coronary Heart Disease
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
This double-blind, randomized, placebo-controlled, multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome (ACS).
- Trial name
- NCT01323153
- Testing
- dalcetrapib
- Where
- 33 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Acute Ischemic Stroke
A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke
MT200605 is an agonist of the receptor tyrosine kinase B (TrkB). It exerts brain-derived neurotrophic factor (BDNF)-like effects, protecting the structure and function of neural tissues in the brain.
- Trial name
- NCT07205328
- Testing
- MT200605
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Ischemic Stroke
IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in a 24 hour window, in patients with an acute ischemic stroke in the anterior circulation, who received Mechanical…
- Trial name
- IMPACT-24Bt (NCT01874093)
- Testing
- The Ischemic Stroke System
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- BrainsGate